Last updated: 4 days ago
AstraZeneca's 6-K Report: Breztri's Phase III Trials Transform Asthma Treatment
AstraZeneca's 6-K reveals Breztri's successful Phase III asthma trial results, showing significant lung function improvements and a strong safety profile, paving the way for enhanced treatment options.